Literature DB >> 15551217

Why does HIV infection not lead to disseminated strongyloidiasis?

Mark E Viney1, Michael Brown, Nicholas E Omoding, J Wendi Bailey, Michael P Gardner, Emily Roberts, Dilys Morgan, Alison M Elliott, James A G Whitworth.   

Abstract

We investigated the hypothesis that host immunosuppression due to advancing human immunodeficiency virus (HIV) disease favors the direct development of infective larvae of Strongyloides stercoralis, which may facilitate hyperinfection and, hence, disseminated strongyloidiasis. To do this, we sought correlations between the immune status of the subjects and the development of S. stercoralis infections. Among 35 adults, there were significant negative rank correlations between CD4+ cell counts and the proportions of free-living male and female worms. Thus, in individuals with preserved immune function, direct development of S. stercoralis is favored, whereas, in individuals with lesser immune function, indirect development is relatively more common. These results may explain the notable absence of disseminated strongyloidiasis in advanced HIV disease. Because disseminated infection requires the direct development of infective larvae in the gut, the observed favoring of indirect development in individuals immunosuppressed by advancing HIV disease is not consistent with the promotion of disseminated infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15551217     DOI: 10.1086/425935

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Strongyloidiasis-related deaths in the United States, 1991-2006.

Authors:  Curtis Croker; Roshan Reporter; Matt Redelings; Laurene Mascola
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

2.  Should we look for Strongyloides stercoralis in foreign-born HIV-infected persons?

Authors:  Jara Llenas-García; Silvana Fiorante; Efrén Salto; Diego Maseda; Violeta Rodríguez; Mariano Matarranz; Asunción Hernando; Rafael Rubio; Federico Pulido
Journal:  J Immigr Minor Health       Date:  2013-08

3.  Strongyloides stercoralis hyper-infection syndrome in HIV+/AIDS patients in Iran.

Authors:  A R Meamar; M Rezaian; M Mohraz; R Hadighi; E B Kia
Journal:  Parasitol Res       Date:  2007-03-31       Impact factor: 2.289

4.  Update on strongyloidiasis in the immunocompromised host.

Authors:  Luis A Marcos; Angélica Terashima; Marco Canales; Eduardo Gotuzzo
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

5.  The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells.

Authors:  Rebecca B Blank; Erika W Lamb; Anna S Tocheva; Emily T Crow; K C Lim; James H McKerrow; Stephen J Davies
Journal:  J Infect Dis       Date:  2006-10-23       Impact factor: 5.226

Review 6.  The biology and genomics of Strongyloides.

Authors:  M E Viney
Journal:  Med Microbiol Immunol       Date:  2006-03-15       Impact factor: 3.402

7.  Alcoholism and Strongyloides stercoralis: daily ethanol ingestion has a positive correlation with the frequency of Strongyloides larvae in the stools.

Authors:  Carla Couzi Marques; Maria da Penha Zago-Gomes; Carlos Sandoval Gonçalves; Fausto Edmundo Lima Pereira
Journal:  PLoS Negl Trop Dis       Date:  2010-06-22

8.  Prevalence and correlates of helminth co-infection in Kenyan HIV-1 infected adults.

Authors:  Judd L Walson; Barclay T Stewart; Laura Sangaré; Loice W Mbogo; Phelgona A Otieno; Benjamin K S Piper; Barbra A Richardson; Grace John-Stewart
Journal:  PLoS Negl Trop Dis       Date:  2010-03-30

9.  Strongyloides stercoralis infection in the immunocompromised host.

Authors:  Roshan Ramanathan; Thomas Nutman
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

10.  Prevalence of Strongyloides stercoralis in an urban US AIDS cohort.

Authors:  Linda Nabha; Sonya Krishnan; Roshan Ramanathan; Rojelio Mejia; Gregg Roby; Virginia Sheikh; Isabel McAuliffe; Thomas Nutman; Irini Sereti
Journal:  Pathog Glob Health       Date:  2012-08       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.